Study Protocol – Stage 2 - PQRI

Regulatory perspectives on CQAs, CPPs, and Risk …

Global Regulatory Affairs Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products. 3rd FDA/PQRI Conference on Advancing Product Quality

  Product, Perspective, Regulatory, Risks, Analyses, Combination, Regulatory perspectives on cqas, Cqas, Cpps, Risk analyses for combination products

Hazard & Operability Analysis (HAZOP) 1 Overview

Manufacturing Technology Committee – Risk Management Working Group Risk Management Training Guides Hazard & Operability Analysis (HAZOP) Page 1 of 9 1 Overview Hazard and Operability Analysis (HAZOP) is a …

  Analysis, Risks, Hazards, Hazard amp operability analysis, Operability, Hazop

Failure Modes and Effects Analysis Guide

Manufacturing Technology Committee – Risk Management Working Group Risk Management Training Guides Failure Modes and Effects Analysis Guide 1 Overview Failure Modes and Effects Analysis (FMEA) is …

  Guide, Analysis, Dome, Failure, Effect, Failure modes and effects analysis guide, Failure modes and effects analysis

CMC Regulatory Considerations for …

CMC Regulatory Considerations for Oligonucleotide Drug Products: FDA Perspective Mohan Sapru, M.S., Ph.D. CMC Lead for Cardiovascular and Renal Products

  Drug, Regulatory, Considerations, Cmc regulatory considerations for, Cmc regulatory considerations for oligonucleotide drug, Oligonucleotide

ICH Q12 : A Unique Opportunity to Realize 21st …

ICH Q12 : A Unique Opportunity to Realize 21st Century Quality Vision . Moheb M. Nasr . 3rd FDA/PQRI Conference . March 22, 2017

  Quality, Opportunity, 21st, Century, Vision, Ich q12, Opportunity to realize 21st, Realize, Opportunity to realize 21st century quality vision

INTRODUCTION TO POLYMER ADDITIVES AND …

INTRODUCTION TO POLYMER ADDITIVES AND STABILIZATION Bobbijo van Beusichem, Ph.D., Senior Staff Scientist, Expert Services, Michael A. Ruberto, Ph.D., Head of Regulatory Services, NAFTA, Expert Services

  Introduction, Polymer, Additives, Introduction to polymer additives and, Introduction to polymer additives and stabilization, Stabilization

Thresholds and Best Practices for Extractable and …

Overview of Thresholds and Best Practices for Extractable and Leachables(L&E) 3rd PQRI/FDA Conference on Advancing Product Quality Washington DC, 22 …

  Practices, Practices for extractable and, Extractable, Practices for extractable and leachables, Leachables

Harmonization of Requirements Between ICH Q3D …

Harmonization of Requirements Between ICH Q3D and Pharmacopeias Kahkashan Zaidi, USP PQRI/USP Workshop on Elemental Impurities March 31 – April 1, 2015 USP Rockville, Maryland

  Requirements, Between, Harmonization of requirements between ich q3d, Harmonization

European reflections on reviewing NDAs and …

European reflections on reviewing NDAs and ANDAs for ICH Q3D elemental impurity compliance Diana van Riet-Nales, Medicines Evaluation Board/NL

  European, Compliance, Elemental, Reflections, European reflections on reviewing ndas, Reviewing, Ndas, Ich q3d elemental impurity compliance, Impurity

Recommendations for the Assessment of Blend …

Recommendations for the Assessment of Blend and Content Uniformity: Modern Approaches to Sampling and Testing James K. Drennen, III drennen@duq.edu

  Assessment, Recommendations, Recommendations for the assessment of

3.2.1. Glass containers for pharmaceutical use 01/2008 ...

EUROPEAN PHARMACOPOEIA 7.0 3.2.1. Glass containers for pharmaceutical use 01/2008:30200 3.2. CONTAINERS A container for pharmaceutical use is an article that contains

  Pharmaceutical, Glass, Container, Glass containers for pharmaceutical use

3.2.9. RUBBER CLOSURES FOR CONTAINERS FOR AQUEOUS ...

3.2.9. Rubber closures for containers EUROPEAN PHARMACOPOEIA 7.0 Silicone oil.Calculate the internal surface area of a syringe in square centimetres using the following expression:

á232ñ ELEMENTAL IMPURITIES—LIMITS

Element Table 1. Permitted Daily Exposures for Elemental ImpuritiesClass (Continued) Oral PDE (mg/day)Parenteral PDE (mg/day)Inhalation PDE (mg/day)Silver 2B 150 10 7 Platinum 2B 100 10 1

  Parenteral

Annex 9 Guidelines on packaging for pharmaceutical products

122 General bulk product Any product that has completed all the processing stages up to, but not including, final packaging (1).containers A container for pharmaceutical use is an article which holds or is

  Guidelines, Product, Pharmaceutical, Packaging, Container, Guidelines on packaging for pharmaceutical products

5.7 TESTS FOR PARTICULATE CONTAMINATION

QAS/11.405/Final page 5 Method Mix the contents of the samples by slowly inverting the container 20 times successively. If necessary, cautiously remove the sealing closure.

  Tests, Closures, Container, Contamination, Particulates, 7 tests for particulate contamination

ICH HARMONISED GUIDELINE

GUIDELINE FOR ELEMENTAL IMPURITIES ICH Harmonised Guideline Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 12 November 2014, this guideline is recommended for adoption to the regulatory parties to ICH. TABLE OF CONTENTS

  Guidelines, Ich harmonised guideline, Harmonised